Northland Securities Reiterates Buy Rating for Evgen Pharma PLC (EVG)
Evgen Pharma PLC (LON:EVG)‘s stock had its “buy” rating reissued by investment analysts at Northland Securities in a research note issued to investors on Wednesday. They currently have a GBX 97 ($1.29) target price on the stock. Northland Securities’ price target indicates a potential upside of 424.32% from the stock’s current price.
Shares of Evgen Pharma PLC (EVG) opened at 18.50 on Wednesday. The firm’s market capitalization is GBX 13.56 million. Evgen Pharma PLC has a one year low of GBX 15.25 and a one year high of GBX 30.25. The company’s 50 day moving average price is GBX 17.29 and its 200 day moving average price is GBX 18.99.
About Evgen Pharma PLC
Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane.
Receive News & Ratings for Evgen Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.